证券代码：688056 证券简称：莱伯泰科 公告编号：2025-016 北京莱伯泰科仪器股份有限公司 第四届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京莱伯泰科仪器股份有限公司（以下简称"公司"）第四届监事会第十五次会议通 知于 2025 年 4 月 11 日以书面形式发出，并于 2025 年 4 月 24 日在公司会议室以现场与 通讯相结合的方式召开。本次会议应到监事 3 人，实到监事 3 人。 本次会议由监事会主席王争奇先生召集并主持。会议的召开符合法律、行政法规、 部门规章和《北京莱伯泰科仪器股份有限公司章程》（以下简称"《公司章程》"）的规定， 合法有效。 二、监事会会议审议情况 经与会监事认真审议，会议形成了如下决议： （一）审议通过《关于公司<2024 年年度报告>及其摘要的议案》 经审议，公司监事会认为公司《2024 年年度报告》的编制和审议程序符合法律、法 规、《公司章程》和公司内部管理制度的各项规定；公司《2024 年年度报告》内容和格 式符合中 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-015 北京莱伯泰科仪器股份有限公司 第四届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京莱伯泰科仪器股份有限公司（以下简称"公司"）第四届董事会第十六 次会议通知于 2025 年 4 月 11 日以书面形式发出，并于 2025 年 4 月 24 日在公司 会议室以现场与通讯相结合的方式召开。会议应出席董事 7 人，实际出席董事 7 人。公司监事和高级管理人员列席了会议。 会议由董事长胡克先生召集并主持。会议的召开符合有关法律、行政法规、 部门规章和《北京莱伯泰科仪器股份有限公司章程》（以下简称"《公司章程》"） 的规定，合法有效。 二、董事会会议审议情况 经与会董事认真审议，会议形成了如下决议： （一）审议通过《关于公司<2024 年年度报告>及其摘要的议案》 经审议，董事会同意公司报出《2024 年年度报告》及其摘要。公司董事会 认为公司《2024 年年度报告》的编制和审议程序符合法律、法规、《公司 ...

北京莱伯泰科仪器股份有限公司 证券代码：688056 证券简称：莱伯泰科 公告编号：2025-005 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利 6.00 元（含税），不进行资本 公积金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购 专用证券账户中股份为基数，具体日期将在权益分派实施公告中明确。在实施权 益分派的股权登记日前公司总股本发生变动的，公司拟维持每股分配比例不变， 相应调整分配总额，并将另行公告具体调整情况。 本次利润分配方案已经公司第四届董事会第十六次会议审议通过，尚 需提交公司股东会审议。 一、 利润分配方案内容 （一）利润分配方案的具体内容 经信永中和会计师事务所（特殊普通合伙）审计，北京莱伯泰科仪器股份有 限公司（以下简称"公司"）2024 年度实现归属于上市公司股东的净利润为人 民币 39,148,080.18 元，截至 2024 年 12 月 31 日，公司期末合并报表未分配利 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-009 北京莱伯泰科仪器股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 关于作废部分已授予尚未归属的限制性股票的公告 北京莱伯泰科仪器股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开第四届董事会第十六次会议、第四届监事会第十五次会议，审议通过了《关于 作废部分已授予尚未归属的限制性股票的议案》。现将相关事项公告如下： 一、激励计划已履行的决策程序 （一）2022 年 12 月 27 日，公司召开第四届董事会第四次会议，审议通过 了《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2022 年限制性股票激励计划实施考核管理办法>的议案》及《关于提请公 司股东大会授权董事会办理 2022 年限制性股票激励计划相关事宜的议案》等议 案。公司独立董事就本激励计划相关议案发表了独立意见。 同日，公司召开第四届监事会第四次会议，审议通过了《关于公司<2022 年 限制性股票激励计划（草案）>及其摘要的议 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥99,050,789.19, a decrease of 6.09% compared to ¥105,478,954.63 in the same period last year[4] - Net profit attributable to shareholders increased by 10.30% to ¥12,766,699.84 from ¥11,574,778.68 year-on-year[4] - The basic earnings per share rose by 11.76% to ¥0.19, compared to ¥0.17 in the previous year[4] - Total operating revenue for Q1 2025 was ¥99,050,789.19, a decrease of 6.8% compared to ¥105,478,954.63 in Q1 2024[19] - Net profit for Q1 2025 increased to ¥12,766,699.84, up 10.3% from ¥11,574,778.68 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.19, compared to ¥0.17 in Q1 2024[21] - The company reported a total comprehensive income of ¥12,278,853.46 for Q1 2025, an increase from ¥11,698,038.01 in Q1 2024[21] Research and Development - Research and development expenses totaled ¥11,358,075.06, down 8.02% from ¥12,347,788.06, with R&D expenses accounting for 11.47% of operating revenue, a decrease of 0.24 percentage points[5] - Research and development expenses for Q1 2025 were ¥11,358,075.06, down from ¥12,347,788.06 in Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥3,144,132.03, compared to -¥1,282,305.88 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was negative at -¥3,144,132.03, worsening from -¥1,282,305.88 in Q1 2024[23] - Net cash flow from financing activities was -314,223.38, indicating a significant outflow[24] - The net increase in cash and cash equivalents was -31,930,462.23, reflecting a decrease in liquidity[24] - The ending balance of cash and cash equivalents was 254,655,508.23, down from the beginning balance of 286,585,970.46[24] - The impact of exchange rate changes on cash and cash equivalents was 66,272.80, showing some resilience against currency fluctuations[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥954,742,314.35, a slight decrease of 0.10% from ¥955,712,276.45 at the end of the previous year[5] - The company's current assets totaled CNY 770,603,668.73, compared to CNY 767,512,121.41 at the end of 2024, indicating a growth of approximately 0.27%[14] - The total liabilities decreased from CNY 138,123,645.32 to CNY 124,462,990.38, reflecting a reduction of about 9.87%[15] - The cash and cash equivalents were reported at CNY 256,033,636.45, down from CNY 288,549,367.12, representing a decline of approximately 11.3%[13] - Accounts receivable increased to CNY 59,858,827.85 from CNY 55,096,497.57, showing an increase of about 8.5%[14] - Inventory levels slightly rose to CNY 171,127,708.48 from CNY 170,415,498.94, indicating a marginal increase of 0.42%[14] - The company reported a significant increase in accounts payable from CNY 39,600,301.87 to CNY 47,945,740.77, which is an increase of approximately 20.5%[15] - The total equity remained stable at CNY 67,452,460.00, unchanged from the previous reporting period[15] Shareholder Information - The net assets attributable to shareholders increased by 1.55% to ¥830,279,323.97 from ¥817,588,631.13 at the end of the previous year[5] - The total number of ordinary shareholders at the end of the reporting period was 3,085[10] - The company's total equity attributable to shareholders increased to ¥830,279,323.97 from ¥817,588,631.13 year-over-year[16] Government Support and Future Outlook - The company received government subsidies amounting to ¥90,935.08, which are expected to have a continuous impact on profits[6] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[12] - The company will not apply new accounting standards starting from 2025, maintaining current reporting practices[24]

Financial Performance - The company's operating revenue for 2024 reached CNY 424.01 million, a year-on-year increase of 1.93%[19]. - Net profit attributable to shareholders for 2024 was CNY 39.15 million, representing a significant increase of 42.03% compared to the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 30.96 million, up 32.88% year-on-year[19]. - The company's cash flow from operating activities increased by CNY 12.55 million, aligning with the growth trend of net profit[21]. - Basic and diluted earnings per share for 2024 were CNY 0.59, a 43.90% increase compared to the previous year[21]. - The net cash flow from operating activities increased by 29.47% to 55.15 million RMB, reflecting improved operational performance[127]. - The company reported a total revenue of 8,580.00 million RMB, with a net profit of 2,134.47 million RMB, representing a year-on-year increase of 5,551.36 million RMB[104]. Dividend and Share Capital - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares (including tax), totaling approximately 40,066,942.80 RMB, which represents 102.35% of the net profit attributable to shareholders for the year 2024[5]. - As of December 31, 2024, the total share capital is 67,452,460 shares, with 674,222 shares in the repurchase account, resulting in 66,778,238 shares eligible for profit distribution[5]. Research and Development - The proportion of R&D investment to operating revenue was 12.09%, a slight decrease of 0.46 percentage points from the previous year[21]. - Research and development expenses amounted to 51.27 million RMB, accounting for 12.09% of operating revenue[35]. - The company has obtained 19 new authorized patents and 3 new software copyrights during the reporting period, totaling 143 authorized patents and 76 software copyrights[39]. - The company has developed a solid-phase extraction automation platform that is widely used in biological analysis and proteomics research[104]. - The company aims to strengthen its R&D capabilities and product technology levels to maintain competitiveness in the high-end instrument market[40]. Product Development and Innovation - The company successfully launched the LabMS 5000 ICP-MS/MS product, which was included in the "Beijing 2024 Major Technical Equipment Directory" for the medical and health sector[32]. - The company launched the AutoEmpore fully automatic rapid solid-phase extraction instrument, enhancing water sample pretreatment technology[39]. - The company plans to release the I-Lab 180 fully automatic iodine analyzer in September 2024, responding to public health system needs and showcasing its R&D capabilities[74]. - The company has developed multiple sample pretreatment instruments that can directly connect with analytical testing instruments, improving analysis efficiency and accuracy[79]. - The company is focusing on the development of technologies that integrate sample pre-treatment instruments with analytical instruments, enhancing overall workflow efficiency[89]. Market and Industry Trends - The total revenue for the inspection and testing industry reached 467.009 billion yuan in 2023, representing a year-on-year growth of 9%[45]. - The market for experimental analysis instruments is expected to grow due to increasing demand in downstream applications such as environmental monitoring and food safety[72]. - The company is focusing on the development of new analysis instruments and sample pretreatment products, aiming to enhance market share in traditional fields while expanding into new sectors such as renewable energy and biomedicine[75]. - The company aims to enhance detection precision, efficiency, and safety by improving instrument performance and analysis technology[45]. Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[4]. - The company has a strong internal control system and has not identified any significant internal control deficiencies during the reporting period[46]. - The company has not reported any special arrangements for corporate governance[7]. - The company has retained its accounting firm for the upcoming fiscal year as part of its governance strategy[184]. Risks and Challenges - The company faces risks related to product development failures, which could impact its technological advantages and long-term growth[116]. - The company is exposed to foreign exchange risks due to its import and export activities, particularly with USD and EUR transactions[123]. - The company must navigate macroeconomic fluctuations and changes in national policies that could affect its operations[125]. Strategic Initiatives - The company plans to enhance its brand promotion through a combination of online and offline strategies, focusing on emerging industries and market segments[43]. - The company aims to provide customized solutions by integrating sample pretreatment and analytical testing instruments, shifting from traditional sales models[86]. - The company plans to improve its product line by developing new technologies and products, including mobile detection instruments and sample pretreatment products, to meet diverse customer needs[173].

北京莱伯泰科仪器股份有限公司 2024 年度 内部控制审计报告 索引 页码 内部控制审计报告 1-2 联系申话: 信永中和会计师事务所| 北京市东城区朝阳门北大街 telephone: 8 号富华大厦 A 座 9 层 +86 (010) 6554 2288 +86 (010) 65 blic accountants 北京莱伯泰科仪器股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计 了北京莱伯泰科仪器股份有限公司(以下简称莱伯泰科公司)2024年12月31日财务报 告内部控制的有效性。 一、企业对内部控制的责任 9/F. Block A. Fu Hua Mansion No.8. Chaovangmen Beidaiie Donachena District. Beijin 100027. P.R.China +86 (010) 6554 7190 内部控制审计报告 XYZH/2025BJAA2B0240 北京莱伯泰科仪器股份有限公司 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定,建立健全和有效实施内部控制,并评价其有效 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: （86-10） 5809-1000 传真: （86-10） 5809-1100 北京市竞天公诚律师事务所 关于北京莱伯泰科仪器股份有限公司 2022 年限制性股票激励计划 部分已授予但尚未归属的限制性股票作废相关事项的 法律意见书 致：关于北京莱伯泰科仪器股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受北京莱伯泰科仪器股 份有限公司（以下简称"公司"）的委托，就公司2022年限制性股票激励计划（以 下简称"激励计划"或"本激励计划"或"本次激励计划"）相关事宜担任专项 法律顾问，并就本激励计划部分已授予但尚未归属的限制性股票作废相关事项出 具本法律意见书。 为出具本法律意见书，本所律师审阅了《北京莱伯泰科仪器股份有限公司 2022年限制性股票激励计划（草案）》（以下简称"《激励计划》"）、《北京 莱伯泰科仪器股份有限公司2022年限制性股票激励计划实施考核管理办法》（以 下简称"《考核办法》"）、《北京莱伯泰科仪器股份有限公司2022年限制性股 票激励计划首次授予激励对象名单（截止首次授予日）》、《 ...

| 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-4 | | 公司财务报表 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并股东权益变动表 | 9-10 | | — | 母公司股东权益变动表 | 11-12 | | — | 财务报表附注 | 13-88 | 联系电话: +86 (010) 6554 2288 信永中和会计师事务所| 北京市东城区朝阳门北大街 8 号富华大厦 A 座 9 层 9/F. Block A. Fu Hua Mansion No.8. Chaoyangmen Beidajie Donachena District. Beijing 100027. P.R.China 北京莱伯泰科仪器股份有限公司 2024 年度 审计报告 +86 (010) 6554 2288 +86 (010) 6554 7190 +86 (010) 6 ...

北京莱伯泰科仪器股份有限公司 2024 年度 +86 (010) 6554 7190 +86 (010) 6554 7190 募集资金年度存放与使用情况鉴证报告 XYZH/2025BJAA2B0241 募集资金年度存放与使用情况鉴证报告 | 索引 | | 页码 | | --- | --- | --- | | 鉴证报告 | | 1-2 | | 关于募集资金 | 2024 年度存放与使用情况的专项报告 | 1-15 | 联系申话: +86 (010) 6554 2288 信永中和会计师事务所| 北京市东城区朝阳门北大街 telephone: +86 (010) 6554 2288 8 号富华大厦 A 座 9 层 9/F. Block A. Fu Hua Mansion No.8. Chaovangmen Beidaiie. ShineWing 佳直· Donachena District, Beijing, certified public accountants 100027. P.R.China facsimile· 北京莱伯泰科仪器股份有限公司 北京莱伯泰科仪器股份有限公司全体股东: 我们对后附的北京莱伯泰 ...